Total Ab ELISA for SARS-CoV-2 Virus (COVID-19)
Serological and Virological Markers of COVID-19
Wantai SARS-CoV-2 Ab ELISA is a highly sensitive and specific diagnostic kit intended for high-throughput, fast antibody screening for patients suspected for COVID-19 infection.
Interested in learning more about Wantai SARS-CoV-2 Ab ELISA?
Contact Us Today
COVID-19 serological markers dynamics (Total Ab/IgM/IgG):
- 20%-40% of the patients developed antibodies on days 0-7 after onset
- 60%-70% of the patients developed antibodies on days 8-11 after onset
- > 90% of the patients had detectable levels of antibodies starting from day 12 after onset
COVID-19 molecular marker dynamics (RNA):
- RNA was detected in 60-75% of the patients on days 0-8 after onset
- 60%-70% of the patients developed antibodies on days 8-11 after onset
- >RNA levels decrease to 40-50% starting from day 9 after onset
For prescription use only.
For in vitro diagnostic use only.
For use under Food and Drug Administration’s Emergency Use Authorization (EUA) only.